Compare Ascendis Pharma A/S (ASND) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs VanEck Rare Earth/Strategic Metals — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while VanEck Rare Earth/Strategic Metals trades at $78. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals.
| ASND | REMX | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Sector/Thematic |
52-Week High | $277.18 | $109.53 |
52-Week Low | $163.32 | $46.34 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
REMX trades at $79.76, down 0.34% with a bearish technical signal from moving averages but oversold RSI readings. Recent news highlights rare earth metals' strategic importance amid China's export controls and AI infrastructure demand. The ETF hit a 52-week high of $104.26 in April 2026 (Defense World, 2026-04-19), but current levels reflect a pullback from recent peaks.
Outlook hinges on commodity cycle momentum and geopolitical supply dynamics, offering growth exposure but with high volatility risks. Concentration in rare earths and lithium makes it sensitive to policy shifts and demand fluctuations, warranting cautious portfolio allocation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →
